Table 2.

Ophthalmic Artery Resistive Index (OA-RI) Changes After Repeated (30 µL/eye, BID) VEH, NCX 470, LUM, or BIM Treatments in ET-1-Treated Eyes

	Ophthalmic Artery Resistive Index (OA-RI)
Time After ET-1 First Dose	Week 0 Baseline	Week 2 ET-1	Week 3 ET-1 + VEH or Test Items	Week 4 ET-1 + VEH or Test Items	Week 5 ET-1 + VEH or Test Items	Week 6 ET-1 + VEH or Test Items
VEH	0.36 ± 0.02	0.43 ± 0.03	0.49 ± 0.01	0.50 ± 0.02	0.52 ± 0.02	0.55 ± 0.01
NCX 470	0.34 ± 0.02	0.43 ± 0.02	0.38 ± 0.01a	0.34 ± 0.02a,b	0.33 ± 0.01a,b	0.33 ± 0.01a,b
LUM	0.38 ± 0.03	0.43 ± 0.03	0.41 ± 0.04	0.45 ± 0.02	0.44 ± 0.01a	0.43 ± 0.02a
BIM	0.31 ± 0.02	0.39 ± 0.03	0.43 ± 0.02a	0.41 ± 0.03a	0.41 ± 0.02a	0.44 ± 0.01a

Week 0 refers to baseline OA-RI; week 2 refers to OA-RI values registered in eyes treated for 2 weeks with ET-1 (twice/week, 200 µL of 250 nM); weeks 3, 4, 5, and 6 refer to OA-RI values registered in eyes treated with ET-1 + VEH, (n = 7) or test items (NCX 470, n = 7; LUM, n = 4; BIM, n = 6). Data are reported as mean ± SEM, multiple t-test with Welch correction.

^a p < 0.05 versus VEH.

^b p < 0.05 versus LUM or BIM at the same time point.